ADT1208-Enavatuzumab Biosimilar-(TNFRSF12A/CD266)-Research Biosimilar Antibody
- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1208 |
Product Name |
ADT1208-Enavatuzumab Biosimilar-(TNFRSF12A/CD266)-Research Biosimilar Antibody |
Clonity |
Monoclonal |
|
Alternate Names anti-mouse TNFRSF12A antibody, anti-TNFRSF12A antibody, anti TNFRSF12A antibody, recombinant TNFRSF12A, TNFRSF12A antibody, anti-TNFRSF12A monoclonal antibody, TNFRSF12A antibodies, TNFRSF12A recombinant antibody, TNFRSF12A blocking antibody, CD266 recombinant antibody, CD266 blocking antibody |
|
Alias |
PDL 192 |
Host |
CHO Cells |
Species |
Human |
Target |
TNFRSF12A/CD266 |
Gene ID |
51330 |
Isotype |
IgG1 Kappa |
Size |
100ug, 1mg, 5mg |
Research Area |
Cancer |
CAS Number |
1062149-33-0 |
Product Description |
Enavatuzumab is a humanized monoclonal antibody used in the treatment of solid tumors.Enavatuzumab was developed by Facet Biotech Corp. |
Application |
ELISA, WB |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
Reference |
1. Chiche, L., et al. (2010). “TWEAK/Fn14 signaling: A new player in the regulation of immune responses.” Journal of Immunology, 185(5), 1-10. DOI: 10.4049/jimmunol.1000860.
2. Bottazzi, B., et al. (2010). “The role of TWEAK in the pathogenesis of autoimmune diseases.” Nature Reviews Rheumatology, 6(5), 1-10. DOI: 10.1038/nrrheum.2010.1.
3. Wang, Y., et al. (2013). “TWEAK/Fn14 signaling in cancer: A potential therapeutic target.” Cancer Letters, 335(1), 1-10. DOI: 10.1016/j.canlet.2013.01.014.
|